CDSCO Advisory: The Central Drugs Standard Control Organization (CDSCO) has issued a new advisory on March 11, 2026, to pharmaceutical manufacturers, importers, and marketing authorization holders in India. This directive emphasizes strict adherence to the Drugs and Cosmetics Act, 1940, and Rules, 1945, particularly concerning the promotion of prescription medicines for obesity and metabolic disorders.
The advisory specifically addresses GLP-1 receptor agonists, highlighting concerns over promotional activities that may indirectly market these prescription-only drugs to the public. The CDSCO has underscored that such medications should only be prescribed by registered medical practitioners and in accordance with approved indications.
Furthermore, the regulator has reiterated the prohibition of direct or indirect advertising of prescription drugs to the public, including through print, electronic, digital, or social media platforms. Activities that exaggerate therapeutic claims or guarantee weight-loss outcomes without emphasizing necessary lifestyle changes will be deemed misleading.
The CDSCO has urged stakeholders to comply with ethical marketing standards and maintain robust consumer grievance mechanisms. Companies are also required to submit comprehensive risk management plans to ensure ongoing safety monitoring.
The advisory highlights that obesity is a chronic metabolic condition requiring comprehensive management strategies, including lifestyle interventions. Pharmaceutical therapies should not undermine broader public health initiatives, and firms must ensure their marketing practices align with public health goals.
Published in SouthAsianDesk, March 12, 2026
Follow SouthAsianDesk on X, Instagram and Facebook for insights on business and current affairs from across South Asia.
